Correlation Between Blueprint Medicines and Caribou Biosciences
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Caribou Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Caribou Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Caribou Biosciences, you can compare the effects of market volatilities on Blueprint Medicines and Caribou Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Caribou Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Caribou Biosciences.
Diversification Opportunities for Blueprint Medicines and Caribou Biosciences
-0.48 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Blueprint and Caribou is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Caribou Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Caribou Biosciences and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Caribou Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Caribou Biosciences has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Caribou Biosciences go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Caribou Biosciences
Given the investment horizon of 90 days Blueprint Medicines Corp is expected to under-perform the Caribou Biosciences. But the stock apears to be less risky and, when comparing its historical volatility, Blueprint Medicines Corp is 1.83 times less risky than Caribou Biosciences. The stock trades about -0.44 of its potential returns per unit of risk. The Caribou Biosciences is currently generating about -0.15 of returns per unit of risk over similar time horizon. If you would invest 148.00 in Caribou Biosciences on November 27, 2024 and sell it today you would lose (20.00) from holding Caribou Biosciences or give up 13.51% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Blueprint Medicines Corp vs. Caribou Biosciences
Performance |
| Timeline |
| Blueprint Medicines Corp |
| Caribou Biosciences |
Blueprint Medicines and Caribou Biosciences Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Blueprint Medicines and Caribou Biosciences
The main advantage of trading using opposite Blueprint Medicines and Caribou Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Caribou Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Caribou Biosciences will offset losses from the drop in Caribou Biosciences' long position.| Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
| Caribou Biosciences vs. Intellia Therapeutics | Caribou Biosciences vs. Editas Medicine | Caribou Biosciences vs. Crispr Therapeutics AG | Caribou Biosciences vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Complementary Tools
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |